Alvotech has already recruited more than 40 new science professionals to its team, since it first broke ground in November 2013 with the building of a vast state-of-the-art development and manufacturing facility in the science park of the University of Iceland in Reykjavik.
The facility is scheduled to open early next year and its manpower seems sure to continue growing, both domestically and globally. Back in 2013, Alvotech announced its plans to invest $500 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. The company’s declared ambition at the time was to become a powerful new player in the field of biopharmaceuticals and it is now well on the road toward achieving that goal.
